Peter Ellmark
1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
- The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
- 2018
- Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
- 2017
- Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
- Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
- 2016
- Selective FcγR engagement by human agonistic anti-CD40 antibodies
- 2015
- Kick-starting the cancer-immunity cycle by targeting CD40
- 2014
- Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
- Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer.
- 2009
- Attovial-based antibody nanoarrays.
- 2008
- Detection of pancreatic cancer using antibody microarray-based serum protein profiling